Australian clinical-stage drug development company Noxopharm is pleased to announce peer-reviewed publication of research showing that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177Lu-PSMA-617 and Veyonda® is both safe and delivered promising efficacy outcomes, among them a median overall survival of 17.1 months.
Australian clinical-stage drug
development company Noxopharm is pleased to announce peer-reviewed publication of research
showing that in late-stage prostate cancer patients who have exhausted all
standard treatment options, a combination of 177Lu-PSMA-617 and
Veyonda® is both safe and delivered promising efficacy outcomes,
among them a median overall survival of 17.1 months. The independent authors
noted that the median overall survival in a study conducted in a comparable
patient population (exhausted all standard treatment options; progressive
disease) receiving standard chemotherapy was only 4.5 months.
“This is excellent news for
Noxopharm and adds to the growing evidence that Veyonda® has the
means to become a standard of care drug in late-stage prostate cancer,” said
Noxopharm Executive Chairman and CEO Graham Kelly. “177Lu-PSMA-617 therapy is attracting considerable
international attention as a promising therapy for men with Stage 4 prostate
cancer. It was the subject of a $6 billion series of acquisitions by Novartis
in 2018 and we anticipate it becoming a commercially available drug in 2021. We
see this publication making a solid case for a combination of Veyonda®
and 177Lu-PSMA-617 becoming a standard treatment option in
late-stage prostate cancer, particularly given that the combination was
well-tolerated, even in patients with advanced disease and very limited
survival prospects.”
The publishing journal, European
Urology Oncology, is the first official publication of the European Association
of Urology that is fully devoted to the study of genitourinary cancer. The
publication has been peer-reviewed by a panel of experts in the field. The
authors are renowned medical experts from the Kinghorn Cancer Centre, St
Vincent’s Hospital Sydney, Garvan Institute of Medical Research, Monash
University, Sir Peter MacCallum Department of Oncology (Melbourne University),
and Princess Margaret Cancer Centre, Toronto.
Read the article here: https://euoncology.europeanurology.com/article/S2588-9311(20)30093-6/fulltext
About Noxopharm
Noxopharm Limited (ASX:NOX) is an
Australian clinical-stage drug development company focused on treating cancer
with Veyonda®, its lead drug candidate. Noxopharm also has an active
R&D program for additional drug candidates and is the major shareholder of
U.S. biotechnology company Nyrada Inc. (ASX:NYR).